✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Lumicitabine is an investigational drug.
There have been 7 clinical trials for Lumicitabine. The most recent clinical trial was a Phase 2 trial, which was initiated on October 25th 2016.
The most common disease conditions in clinical trials are Virus Diseases, Respiratory Syncytial Virus Infections, and Respiratory Sounds. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium, and [disabled in preview].
There are twelve US patents protecting this investigational drug and one hundred and seventy-two international patents.
Recent Clinical Trials for Lumicitabine
|Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus||Janssen Research & Development, LLC||Phase 2|
|A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants||Janssen Research & Development, LLC||Phase 1|
|A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants||Janssen Research & Development, LLC||Phase 1|
Top disease conditions for Lumicitabine
Top clinical trial sponsors for Lumicitabine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Lumicitabine||See Plans and Pricing||Substituted nucleosides, nucleotides and analogs thereof||Alios BioPharma, Inc. (South San Francisco, CA)||See Plans and Pricing|
|Lumicitabine||See Plans and Pricing||RSV antiviral pyrazolo- and triazolo-pyrimidine compounds||Janssen Sciences Ireland UC (Little Island, Co Cork, IE)||See Plans and Pricing|
|Lumicitabine||See Plans and Pricing||Antiviral compounds||Alios BioPharma, Inc. (South San Francisco, CA)||See Plans and Pricing|
|Lumicitabine||See Plans and Pricing||Substituted nucleosides, nucleotides and analogs thereof||ALIOS BIOPHARMA, INC. (South San Francisco, CA)||See Plans and Pricing|
|Lumicitabine||See Plans and Pricing||Methods of preparing substituted nucleoside analogs||ALIOS BIOPHARMA, INC. (South San Francisco, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Lumicitabine||Australia||AU2015280234||2034-06-24||See Plans and Pricing|
|Lumicitabine||Canada||CA2952959||2034-06-24||See Plans and Pricing|
|Lumicitabine||China||CN106604734||2034-06-24||See Plans and Pricing|
|Lumicitabine||Eurasian Patent Organization||EA201692537||2034-06-24||See Plans and Pricing|
|Lumicitabine||European Patent Office||EP3160475||2034-06-24||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|